• Blackstone Life Sciences agreed to provide Pfizer up to $1.5 billion through 2028 to fund berobenatide development.
• The investigational monthly GLP-1 receptor agonist is being studied for chronic weight management and obesity-related conditions.
• Milestone payments depend on U.S. approval of monthly injectable berobenatide monotherapy for chronic weight management and achievement of commercial sales milestones.
• Pfizer retains full operational control and decision-making over the program; the funding partner acquires no rights or ownership in berobenatide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blackstone Inc. published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.